Merck and Moderna’s established 2016 oncology collaboration, deepened by Merck’s $450 million in option payments and equal cost/profit sharing on the individualized neoantigen therapy intismeran autogene, continues to drive market-implied odds against a 2026 merger or acquisition announcement. Recent Phase 3 success in melanoma, reported in mid-August 2026, has reinforced the partnership model rather than prompting consolidation, while Merck pursues separate bolt-on deals such as the $6.7 billion Terns Pharmaceuticals acquisition and $9.2 billion Cidara transaction to bolster its pipeline. With Merck’s market capitalization exceeding $330 billion versus Moderna’s roughly $25 billion, full integration remains structurally improbable absent a major strategic pivot. Tail risks include unforeseen regulatory or competitive pressures that could alter capital allocation, though no such catalysts have materialized.
Resumo experimental gerado por IA com dados do Polymarket. Isto não é aconselhamento de trading e não tem qualquer papel na resolução deste mercado. · AtualizadoSim
1% chance
NOVO
NOVO
31 dez 2026
Sim
1% chance
NOVO
NOVO
31 dez 2026
This market will resolve to "Yes" if it is officially announced that Merck & Co. (MRK) will be, has been, or is being acquired by or merged with Moderna (MRNA), or vice versa, by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
A qualifying merger or acquisition must encompass both MRK and MRNA or their subsidiaries.
An announcement by MRK or MRNA within this market's timeframe will qualify for a "Yes" resolution, regardless of whether or when the announced acquisition/merger actually occurs.
A bid or offer announcement without the indication of a settled agreement will not qualify.
Announcements of partial sales may count, as long as the acquiring company announces the acquisition of a controlling interest in the other company. A "controlling interest" refers to a change in ownership sufficient to control the company's strategic decisions (typically more than 50% of equity, or equivalent control via voting and governance rights). Transactions or investments that do not result in a transfer of controlling interest will not count.
The primary resolution source for this market will be official information from MRK and MRNA; however, a consensus of credible reporting may also be used.Merck and Moderna’s established 2016 oncology collaboration, deepened by Merck’s $450 million in option payments and equal cost/profit sharing on the individualized neoantigen therapy intismeran autogene, continues to drive market-implied odds against a 2026 merger or acquisition announcement. Recent Phase 3 success in melanoma, reported in mid-August 2026, has reinforced the partnership model rather than prompting consolidation, while Merck pursues separate bolt-on deals such as the $6.7 billion Terns Pharmaceuticals acquisition and $9.2 billion Cidara transaction to bolster its pipeline. With Merck’s market capitalization exceeding $330 billion versus Moderna’s roughly $25 billion, full integration remains structurally improbable absent a major strategic pivot. Tail risks include unforeseen regulatory or competitive pressures that could alter capital allocation, though no such catalysts have materialized.
This market will resolve to "Yes" if it is officially announced that Merck & Co. (MRK) will be, has been, or is being acquired by or merged with Moderna (MRNA), or vice versa, by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
A qualifying merger or acquisition must encompass both MRK and MRNA or their subsidiaries.
An announcement by MRK or MRNA within this market's timeframe will qualify for a "Yes" resolution, regardless of whether or when the announced acquisition/merger actually occurs.
A bid or offer announcement without the indication of a settled agreement will not qualify.
Announcements of partial sales may count, as long as the acquiring company announces the acquisition of a controlling interest in the other company. A "controlling interest" refers to a change in ownership sufficient to control the company's strategic decisions (typically more than 50% of equity, or equivalent control via voting and governance rights). Transactions or investments that do not result in a transfer of controlling interest will not count.
The primary resolution source for this market will be official information from MRK and MRNA; however, a consensus of credible reporting may also be used.
A qualifying merger or acquisition must encompass both MRK and MRNA or their subsidiaries.
An announcement by MRK or MRNA within this market's timeframe will qualify for a "Yes" resolution, regardless of whether or when the announced acquisition/merger actually occurs.
A bid or offer announcement without the indication of a settled agreement will not qualify.
Announcements of partial sales may count, as long as the acquiring company announces the acquisition of a controlling interest in the other company. A "controlling interest" refers to a change in ownership sufficient to control the company's strategic decisions (typically more than 50% of equity, or equivalent control via voting and governance rights). Transactions or investments that do not result in a transfer of controlling interest will not count.
The primary resolution source for this market will be official information from MRK and MRNA; however, a consensus of credible reporting may also be used.
Mercado Aberto: Aug 19, 2026, 3:58 PM ET
Volume
$425Data de Término
1 jan 2027Mercado Aberto
Aug 19, 2026, 3:58 PM ETResolver
0x65070BE91...This market will resolve to "Yes" if it is officially announced that Merck & Co. (MRK) will be, has been, or is being acquired by or merged with Moderna (MRNA), or vice versa, by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
A qualifying merger or acquisition must encompass both MRK and MRNA or their subsidiaries.
An announcement by MRK or MRNA within this market's timeframe will qualify for a "Yes" resolution, regardless of whether or when the announced acquisition/merger actually occurs.
A bid or offer announcement without the indication of a settled agreement will not qualify.
Announcements of partial sales may count, as long as the acquiring company announces the acquisition of a controlling interest in the other company. A "controlling interest" refers to a change in ownership sufficient to control the company's strategic decisions (typically more than 50% of equity, or equivalent control via voting and governance rights). Transactions or investments that do not result in a transfer of controlling interest will not count.
The primary resolution source for this market will be official information from MRK and MRNA; however, a consensus of credible reporting may also be used.Merck and Moderna’s established 2016 oncology collaboration, deepened by Merck’s $450 million in option payments and equal cost/profit sharing on the individualized neoantigen therapy intismeran autogene, continues to drive market-implied odds against a 2026 merger or acquisition announcement. Recent Phase 3 success in melanoma, reported in mid-August 2026, has reinforced the partnership model rather than prompting consolidation, while Merck pursues separate bolt-on deals such as the $6.7 billion Terns Pharmaceuticals acquisition and $9.2 billion Cidara transaction to bolster its pipeline. With Merck’s market capitalization exceeding $330 billion versus Moderna’s roughly $25 billion, full integration remains structurally improbable absent a major strategic pivot. Tail risks include unforeseen regulatory or competitive pressures that could alter capital allocation, though no such catalysts have materialized.
This market will resolve to "Yes" if it is officially announced that Merck & Co. (MRK) will be, has been, or is being acquired by or merged with Moderna (MRNA), or vice versa, by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
A qualifying merger or acquisition must encompass both MRK and MRNA or their subsidiaries.
An announcement by MRK or MRNA within this market's timeframe will qualify for a "Yes" resolution, regardless of whether or when the announced acquisition/merger actually occurs.
A bid or offer announcement without the indication of a settled agreement will not qualify.
Announcements of partial sales may count, as long as the acquiring company announces the acquisition of a controlling interest in the other company. A "controlling interest" refers to a change in ownership sufficient to control the company's strategic decisions (typically more than 50% of equity, or equivalent control via voting and governance rights). Transactions or investments that do not result in a transfer of controlling interest will not count.
The primary resolution source for this market will be official information from MRK and MRNA; however, a consensus of credible reporting may also be used.
A qualifying merger or acquisition must encompass both MRK and MRNA or their subsidiaries.
An announcement by MRK or MRNA within this market's timeframe will qualify for a "Yes" resolution, regardless of whether or when the announced acquisition/merger actually occurs.
A bid or offer announcement without the indication of a settled agreement will not qualify.
Announcements of partial sales may count, as long as the acquiring company announces the acquisition of a controlling interest in the other company. A "controlling interest" refers to a change in ownership sufficient to control the company's strategic decisions (typically more than 50% of equity, or equivalent control via voting and governance rights). Transactions or investments that do not result in a transfer of controlling interest will not count.
The primary resolution source for this market will be official information from MRK and MRNA; however, a consensus of credible reporting may also be used.
Volume
$425Data de Término
1 jan 2027Mercado Aberto
Aug 19, 2026, 3:58 PM ETResolver
0x65070BE91...Merck and Moderna’s established 2016 oncology collaboration, deepened by Merck’s $450 million in option payments and equal cost/profit sharing on the individualized neoantigen therapy intismeran autogene, continues to drive market-implied odds against a 2026 merger or acquisition announcement. Recent Phase 3 success in melanoma, reported in mid-August 2026, has reinforced the partnership model rather than prompting consolidation, while Merck pursues separate bolt-on deals such as the $6.7 billion Terns Pharmaceuticals acquisition and $9.2 billion Cidara transaction to bolster its pipeline. With Merck’s market capitalization exceeding $330 billion versus Moderna’s roughly $25 billion, full integration remains structurally improbable absent a major strategic pivot. Tail risks include unforeseen regulatory or competitive pressures that could alter capital allocation, though no such catalysts have materialized.
Resumo experimental gerado por IA com dados do Polymarket. Isto não é aconselhamento de trading e não tem qualquer papel na resolução deste mercado. · Atualizado
Cuidado com os links externos.
Cuidado com os links externos.
Frequently Asked Questions